Integrated Wellness · Research education
Compare the science.
Put two to four molecules side by side. Similar goals do not mean similar mechanisms, evidence or risks.
Choose your molecules
3 of 4 selected · Choose at least 2
Explore a comparison:
On smaller screens, scroll the table sideways to see each molecule.
| Research dimension | Thymosin Alpha-1 Human research | KPV Preclinical | LL-37 Human research |
|---|---|---|---|
| Biological classification | Thymosin alpha-1 (thymalfasin), a 28-amino-acid peptide | Lys-Pro-Val tripeptide related to alpha-MSH | Human cathelicidin antimicrobial peptide |
| Mechanism & pathway | Investigated for modulation of innate and adaptive immune pathways, including antigen presentation and T-cell function. Context-dependent immune effects are not a universal enhancement mechanism. | Cell and mouse experiments examine PepT1-mediated uptake and modulation of NF-κB and MAPK inflammatory pathways. | Interacts with microbial membranes and host immune pathways. Antimicrobial, inflammatory and repair-related effects vary by tissue and experimental context. |
| Investigated applications | Immune regulation in infection and other disease-specific studies. | Intestinal inflammatory signaling and experimental colitis. | Antimicrobial defense, wound biology and immune signaling. |
| Evidence quality | Human research | Preclinical | Human research |
| What remains uncertain | Trials address different diseases, populations and regimens. The linked review does not establish a general immune-boosting effect or US approval. | PepT1-mediated uptake and inflammatory changes were studied in cells and mouse colitis models, not proof of benefit for human IBD. | The linked review is background biology, not proof of systemic infection treatment. Limited clinical wound research cannot validate unrelated systemic uses. |
| Safety considerations | FDA considers safety information inadequate for nominated compounded products and identifies immunogenicity concerns. Immune disease, transplantation and immunosuppressants warrant particular clinical scrutiny. | FDA reports no identified human exposure data for nominated KPV drug products. Safety, interactions and effects in vulnerable populations are unknown. | FDA cites inadequate human safety information and nonclinical reproductive and protumorigenic concerns in some tissues. Inflammatory effects are context-dependent. |
| Regulatory classification | Not FDA-approvedNo FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval. | Not FDA-approvedNo FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval. | Not FDA-approvedNo FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval. |
Comparing molecules is not a recommendation to combine them. Clinical evidence for one product or indication cannot establish another’s safety or effectiveness. Open each profile for study types, source links and important evidence limitations.